Circulating FGF21 levels are related to nutritional status and metabolic but not hormonal disturbances in polycystic ovary syndrome.

OBJECTIVE The aim of this study was to analyse relationships between plasma fibroblast growth factor 21 (FGF21) levels and nutritional status, and metabolic and hormonal disturbances in polycystic ovary syndrome (PCOS) women. DESIGN AND SETTING A cross-sectional study involving 85 PCOS (48 obese) and 72 non-PCOS women (41 obese) was conducted to evaluate the relationship between FGF21 levels and PCOS. METHODS Anthropometric parameters and body composition were determined. In the fasting state; serum concentrations of glucose, androgens, FSH, LH, SHBG, insulin and FGF21 were measured. RESULTS Plasma FGF21 levels were significantly higher in obese women compared with normal-weight women in both PCOS and non-PCOS subgroups (120.3 (18.2-698) vs 62.3 (16.4-323.6) pg/ml, P<0.05 and 87.2 (12.9-748.4) vs 62.9 (18.0-378.8) pg/ml, P<0.05 respectively). Additionally, circulating FGF21 levels were significantly higher in the obese PCOS subgroup compared with the non-PCOS subgroup (120.3 (18.2-698.0) vs 87.2 (12.9-748.4) pg/ml, P<0.05). Circulating FGF21 levels were proportional to BMI (R=0.27; P<0.001), body fat mass (R=0.24; P<0.01) and percentage (R=0.24; P<0.01), as well as waist circumference (R=0.26; P<0.01). Additionally, plasma insulin and homeostasis model assessment of insulin resistance (HOMA-IR) values were related to FGF21 levels (R=0.44; P<0.001 and R=0.19; P<0.05 respectively). In multiple regression analysis, circulating FGF21 level variability was explained by HOMA-IR values and fat percentage, as well as waist circumference, but not correlated with oestradiol levels and free androgen index values. CONCLUSIONS Higher circulating FGF21 levels are related to nutritional status and insulin resistance independent of PCOS. Increased FGF21 is associated with metabolic but not hormonal disturbances.

[1]  H. J. Yoo,et al.  Effects of a three‐month combined exercise programme on fibroblast growth factor 21 and fetuin‐A levels and arterial stiffness in obese women , 2011, Clinical endocrinology.

[2]  A. Pfeiffer,et al.  Relation between fibroblast growth factor-21, adiposity, metabolism, and weight reduction. , 2011, Metabolism: clinical and experimental.

[3]  J. Chudek,et al.  Plasma omentin and adiponectin levels as markers of adipose tissue dysfunction in normal weight and obese women with polycystic ovary syndrome , 2014, Clinical endocrinology.

[4]  J. Chudek,et al.  Circulating apelin level in relation to nutritional status in polycystic ovary syndrome and its association with metabolic and hormonal disturbances , 2013, Clinical endocrinology.

[5]  Feng Liu,et al.  Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans , 2008, Diabetes.

[6]  M. Espeland,et al.  Liver fat and SHBG affect insulin resistance in midlife women: The Study of Women’s Health Across the Nation (SWAN) , 2012, Obesity.

[7]  T. Reinehr,et al.  Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. , 2012, The Journal of clinical endocrinology and metabolism.

[8]  M. Eriksson,et al.  The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. , 2008, Cell metabolism.

[9]  S. Caprio,et al.  Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage. , 2013, The Journal of clinical endocrinology and metabolism.

[10]  S. Bornstein,et al.  Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. , 2013, Cell metabolism.

[11]  Jun Li,et al.  Amelioration of Type 2 Diabetes by Antibody-Mediated Activation of Fibroblast Growth Factor Receptor 1 , 2011, Science Translational Medicine.

[12]  A. Xu,et al.  Research Design and Methods , 2005, Hormone Research in Paediatrics.

[13]  Kenny K. Wong,et al.  Adipose Fibroblast Growth Factor 21 Is Up-Regulated by Peroxisome Proliferator-Activated Receptor γ and Altered Metabolic States , 2008, Molecular Pharmacology.

[14]  T. Arora,et al.  Treating Diabetes and Obesity with an FGF21-Mimetic Antibody Activating the βKlotho/FGFR1c Receptor Complex , 2012, Science Translational Medicine.

[15]  N. Itoh,et al.  Functional evolutionary history of the mouse Fgf gene family , 2008, Developmental dynamics : an official publication of the American Association of Anatomists.

[16]  S. Sahin,et al.  Fibroblast growth factor 21 and its relation to metabolic parameters in women with polycystic ovary syndrome , 2014, Scandinavian journal of clinical and laboratory investigation.

[17]  T. Lundåsen,et al.  PPARalpha is a key regulator of hepatic FGF21. , 2007, Biochemical and biophysical research communications.

[18]  B. Zahorska-Markiewicz,et al.  Is the polycystic ovary syndrome associated with chronic inflammation per se? , 2007, European journal of obstetrics, gynecology, and reproductive biology.

[19]  M. Martínez-Chantar,et al.  Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. , 2010, Gastroenterology.

[20]  M. Konishi,et al.  Identification of a novel FGF, FGF-21, preferentially expressed in the liver. , 2000, Biochimica et biophysica acta.

[21]  N. Lundbom,et al.  Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins. , 2011, The Journal of clinical endocrinology and metabolism.

[22]  P. Arner,et al.  FGF21 attenuates lipolysis in human adipocytes – A possible link to improved insulin sensitivity , 2008, FEBS letters.

[23]  M. Matoulek,et al.  Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor‐21 in patients with type 2 diabetes and obesity , 2009, Clinical endocrinology.

[24]  F. Villarroya,et al.  TNF-α represses β-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. , 2012, Endocrinology.

[25]  D. Moller,et al.  Fibroblast growth factor 21 corrects obesity in mice. , 2008, Endocrinology.

[26]  Jing Xu,et al.  A Novel Approach to Improve the Function of FGF21 , 2013, BioDrugs.

[27]  J. Gromada,et al.  FGF-21 as a novel metabolic regulator. , 2005, The Journal of clinical investigation.

[28]  LenaPersson,et al.  Endogenous Estrogens Lower Plasma PCSK9 and LDL Cholesterol But Not Lp(a) or Bile Acid Synthesis in Women , 2012 .

[29]  R. Serter,et al.  Serum fibroblast growth factor 21 levels in polycystic ovary syndrome , 2010, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[30]  M. Huang,et al.  [Plasma fibroblast growth factor-21 and abdominal obesity]. , 2010, Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition.

[31]  Richard S Legro,et al.  Polycystic ovary syndrome , 2007, The Lancet.

[32]  C. Aguilar-Salinas,et al.  Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels. , 2010, European journal of endocrinology.

[33]  E. Diamanti-Kandarakis,et al.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. , 2012, Endocrine reviews.

[34]  I. Yusuf,et al.  Serum adiponectin and resistin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome , 2011, Therapeutic advances in endocrinology and metabolism.

[35]  J. Chudek,et al.  Are plasma levels of visfatin and retinol-binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome? , 2012, European journal of obstetrics, gynecology, and reproductive biology.

[36]  A. Keech,et al.  Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes. , 2012, The Journal of clinical endocrinology and metabolism.

[37]  H. Fu,et al.  The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. , 2013, Cell metabolism.

[38]  Christopher C. Frye,et al.  Rational Design of a Fibroblast Growth Factor 21-Based Clinical Candidate, LY2405319 , 2013, PloS one.

[39]  R. Lobo,et al.  Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. , 1999, The Journal of clinical endocrinology and metabolism.

[40]  J. Flier,et al.  Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State , 2010, Diabetes.

[41]  S. Lamberts,et al.  Clinical endocrinology and metabolism. Gut endocrine tumours. , 2004, Best practice & research. Clinical endocrinology & metabolism.

[42]  B. Fauser,et al.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). , 2004, Human reproduction.

[43]  Jieming Li,et al.  Serum Concentrations of Fibroblast Growth Factors 19 and 21 in Women with Gestational Diabetes Mellitus: Association with Insulin Resistance, Adiponectin, and Polycystic Ovary Syndrome History , 2013, PloS one.